Boards have long shunned speaking with investors. Now, they are being pressed to open up. The NYT reports.» Read More
Chief executives of two of the nation's largest companies say focusing on environmental challenges is good business.
Last year Genentech shares traded as high as nearly 88 dollars, but ended 2007 around 67 bucks. But according to the company's new proxy statement all of Genentech's top-tier executives saw their total compensation go up.
Northrop Grumman CEO Ronald Sugar says his company plans to build four factories in the United States as part of a partnership with European Aeronautic Defence and Space (EADS).
The last week has seen the Fed throw more money at the banking system -- and the markets have apparently shrugged-off the positives. After a brief flattening in the Treasury curve, the markets returned to their default view that the Fed has lost control of the situation and credit market distress is the most important story in the room.
The subprime crisis may have wiped billions of dollars off the value of global real estate markets, but it is much easier to make money in today's market than a year ago, the joint CEO of RREEF Europe told Reuters.
Finally, a stock that touches on three key trends: animal feed, biofuel and the environment.
CEO Linda McMahon explains why her company's a true intercontinental champion.
You figured the automakers would eventually scream "UNCLE!" I'm not sure it's a scream, but it's more than just a whisper. One thing is clear: the automakers are once again turning to 0 percent financing to spur sales that are stalling.
The chief executive of Bear Stearns told CNBC that despite recent market volatility, he is not aware of any imminent threat to the Wall Street investment bank's liquidity.
Everyone's favorite small-cap biotech put out a press release this morning, announcing that the Food and Drug Administration has agreed to change the Special Protocol Assessment (SPA) for Dendreon's Provenge.
The president and chief executive of the Walt Disney Company says his company is not recession-proof, but it is positioned well enough to avoid being badly hurt in an downturn.
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.
Despite signs of an economic pullback in the United States, Freeport McMoran Copper & Gold is not worried about its business. Why? China is likely to pick up the slack.
U.S. bank Merrill Lynch will not need to return to the market again following the turbulence in credit markets that forced it to raise nearly $13 billion, its chief executive was quoted as saying.
This is quite possibly the last momentum stock around. Here's why the CEO thinks the growth will continue.
The risk will make you queasy, but the reward might be worth it.
First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.
The stunning pay packages of executives at financial groups hammered by the U.S. mortgage crisis came in for stinging criticism from Democratic lawmakers and investor advocates at a congressional hearing Friday.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
Countrywide Financial CEO Angelo Mozilo told a congressional panel Friday that he is "extremely concerned" that recent tightening of mortgage underwriting criteria has gone too far.